FIELD: medicine.
SUBSTANCE: present disclosure provides a novel ophthalmic composition containing rebamipide and a method for production thereof.
EFFECT: according to the present disclosure, the ophthalmic composition retains its transparency for a long period of time even in the pH range from the physiologically neutral to the weakly basic, which does not lead to damage to the cornea and conjunctiva of the patient suffering from dry eye, and has improved stability, at which there is no recovery of dispersity.
8 cl, 15 tbl, 38 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS | 2009 |
|
RU2538694C2 |
| ORAL PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF "DRY EYE" SYNDROME CONTAINING REBAMIPID OR ITS PRECURSOR | 2014 |
|
RU2632107C2 |
| ANDROGEN COMPOSITION FOR TREATING OPHTHALMIC CONDITIONS | 2012 |
|
RU2599036C2 |
| COMPOSITION IN THE FORM OF EYE DROPS TO DECREASE INTRAOCULAR PRESSURE | 2017 |
|
RU2772230C2 |
| OPHTHALMIC NANOEMULSION COMPOSITION CONTAINING CYCLOSINO AND PREPARATION METHOD THEREOF | 2014 |
|
RU2683271C2 |
| OPHTHALMIC COMPOSITION WITH HIGH CONCENTRATION OF OLOPATADINE | 2012 |
|
RU2613715C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING CONJUGATE OF G-CSF | 2011 |
|
RU2519031C1 |
| MULTILAYER FILM FOR MEDICAL SOLUTION CONTAINERS AND CONTAINER COMPRISING SAID FILM | 2008 |
|
RU2447996C2 |
| PARENTERAL LIQUID PREPARATION INCLUDING CARBAMATE COMPOUND | 2017 |
|
RU2761041C2 |
| COMPOSITION OF EYE DROPS | 2017 |
|
RU2753511C2 |
